## Joseph Hung

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4534903/publications.pdf

Version: 2024-02-01

		172457	197818
86	2,816	29	49
papers	citations	h-index	g-index
86	86	86	5.422
00	00	00	5423
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	<i>APOE</i> ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimer's and Dementia, 2022, 18, 2151-2166.	0.8	16
2	DXA-Derived vs Standard Anthropometric Measures for Predicting Cardiometabolic Risk in Middle-Aged Australian Men and Women. Journal of Clinical Densitometry, 2022, 25, 299-307.	1.2	6
3	Validation of ICD-10-AM Coding for Myocardial Infarction Subtype in Hospitalisation Data. Heart Lung and Circulation, 2022, 31, 849-858.	0.4	10
4	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis, 2022, 346, 68-74.	0.8	7
5	Comparing self-reported and measured hypertension and hypercholesterolaemia at standard and more stringent diagnostic thresholds: the cross-sectional 2010–2015 Busselton Healthy Ageing study. Clinical Hypertension, 2022, 28, .	2.0	3
6	Unplanned 30-day readmission, comorbidity, and impact on mortality after incident atrial fibrillation hospitalization in Western Australia, 2001–2015. Heart Rhythm O2, 2022, 3, 511-519.	1.7	2
7	Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Nature Communications, 2022, 13, .	12.8	30
8	Incidence, predictors and mortality risk of new heart failure in patients hospitalised with atrial fibrillation. Heart, 2021, 107, 1320-1326.	2.9	15
9	Can the <scp>CHA<sub>2</sub>DS<sub>2</sub>â€VA</scp> schema be used to decide on anticoagulant therapy in Aboriginal and other Australians with nonâ€valvular atrial fibrillation?. Internal Medicine Journal, 2021, 51, 600-603.	0.8	2
10	Antithrombotic Therapy in Atrial Fibrillation Management in Western Australia: Temporal Trends and Evidence-Treatment Gaps. Heart Lung and Circulation, 2021, 30, 955-962.	0.4	6
11	Prevalence and patterns of multimorbidity in Australian baby boomers: the Busselton healthy ageing study. BMC Public Health, 2021, 21, 1539.	2.9	14
12	Changing age-specific trends in incidence, comorbidities and mortality of hospitalised heart failure in Western Australia between 2001 and 2016. International Journal of Cardiology, 2021, 343, 56-62.	1.7	9
13	Long-term outcomes following rheumatic heart disease diagnosis in Australia. European Heart Journal Open, 2021, 1, .	2.3	11
14	A Validation Study: How Predictive Is a Diagnostic Coding Algorithm at Identifying Rheumatic Heart Disease in Western Australian Hospital Data?. Heart Lung and Circulation, 2020, 29, e194-e199.	0.4	2
15	Rheumatic heart disease in pregnancy: Profile of women admitted to a Western Australian tertiary obstetric hospital. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 302-308.	1.0	4
16	High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. PLoS Biology, 2020, 18, e3000870.	5.6	89
17	Contemporary Incidence and Prevalence of Rheumatic Fever and Rheumatic Heart Disease in Australia Using Linked Data: The Case for Policy Change. Journal of the American Heart Association, 2020, 9, e016851.	3.7	67
18	Long-Term Adherence to Renin–Angiotensin System Inhibitors and β-Blockers After Heart Failure Hospitalization in Senior Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 531-540.	2.0	5

#	Article	lF	Citations
19	Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubic spline analysis of adherence-outcome relationships. Scientific Reports, 2020, 10, 4315.	3.3	9
20	<p>Development and Evaluation of a Prediction Model for Ascertaining Rheumatic Heart Disease Status in Administrative Data</p> . Clinical Epidemiology, 2020, Volume 12, 717-730.	3.0	9
21	Differences in stroke risk and cardiovascular mortality for Aboriginal and other Australian patients with atrial fibrillation. Medical Journal of Australia, 2020, 212, 215-221.	1.7	16
22	Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study. Journal of Lipid Research, 2020, 61, 537-545.	4.2	29
23	Comparison of medication adherence measures derived from linked administrative data and associations with mortality using restricted cubic splines in heart failure patients. Pharmacoepidemiology and Drug Safety, 2020, 29, 208-218.	1.9	11
24	Genome-wide Association Study of Change in Fasting Glucose over time in 13,807 non-diabetic European Ancestry Individuals. Scientific Reports, 2019, 9, 9439.	3.3	5
25	Outcomes of anemic patients presenting with acute coronary syndrome: An analysis of the Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events. Clinical Cardiology, 2019, 42, 791-796.	1.8	8
26	Low positive predictive value of International Classification of Diseases, 10th Revision codes in relation to rheumatic heart disease: a challenge for global surveillance. Internal Medicine Journal, 2019, 49, 400-403.	0.8	19
27	Evaluating recruitment strategies for <scp>AUSPICE</scp> , a large Australian communityâ€based randomised controlled trial. Medical Journal of Australia, 2019, 210, 409-415.	1.7	12
28	Lower serum 25-hydroxyvitamin D is associated with colorectal and breast cancer, but not overall cancer risk: a 20-year cohort study. Nutrition Research, 2019, 67, 100-107.	2.9	14
29	<p>The End Rheumatic Heart Disease in Australia Study of Epidemiology (ERASE) Project: data sources, case ascertainment and cohort profile</p> . Clinical Epidemiology, 2019, Volume 11, 997-1010.	3.0	24
30	A 5αâ€reductase (SRD5A2) polymorphism is associated with serum testosterone and sex hormoneâ€"binding globulin in men, while aromatase (CYP19A1) polymorphisms are associated with oestradiol and luteinizing hormone reciprocally. Clinical Endocrinology, 2019, 90, 301-311.	2.4	3
31	Drivers of hospitalisation trends for non-valvular atrial fibrillation in Western Australia, 2000–2013. International Journal of Cardiology, 2019, 276, 273-277.	1.7	9
32	Under-use of appropriate blood pressure–lowering and lipid-lowering therapy in the Busselton baby boomer population. , 2019, 48, 883-889.		1
33	Serum 25â€hydroxyvitamin D as a predictor of mortality and cardiovascular events: A 20â€year study of a communityâ€based cohort. Clinical Endocrinology, 2018, 88, 154-163.	2.4	19
34	Pleiotropy of cardiometabolic syndrome with obesity-related anthropometric traits determined using empirically derived kinships from the Busselton Health Study. Human Genetics, 2018, 137, 45-53.	3.8	10
35	High-sensitivity cardiac troponin I and risk of cardiovascular disease in an Australianpopulation-based cohort. Heart, 2018, 104, 895-903.	2.9	32
36	Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database. Clinical Epidemiology, 2018, Volume 10, 1181-1194.	3.0	17

#	Article	IF	Citations
37	Patterns of Medicare-funded primary health and specialist consultations in Aboriginal and non-Aboriginal Australians in the two years before hospitalisation for ischaemic heart disease. International Journal for Equity in Health, 2018, 17, 111.	3.5	6
38	Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque. Atherosclerosis, 2018, 275, 232-238.	0.8	21
39	The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2018, 143, 62-70.	2.8	9
40	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung and Circulation, 2018, 27, 1209-1266.	0.4	216
41	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Medical Journal of Australia, 2018, 209, 356-362.	1.7	50
42	High-sensitivity cardiac troponin I and risk of incident atrial fibrillation hospitalisation in an Australian community-based cohort: The Busselton health study. Clinical Biochemistry, 2018, 58, 20-25.	1.9	10
43	Evidenceâ€based pharmacotherapies used in the postdischarge phase are associated with improved oneâ€year survival in senior patients hospitalized with heart failure. Cardiovascular Therapeutics, 2018, 36, e12464.	2.5	7
44	Trends in age- and sex-specific prevalence and incidence of cardiovascular disease in Western Australia. European Journal of Preventive Cardiology, 2018, 25, 1280-1290.	1.8	22
45	Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. Nature Communications, 2017, 8, 14977.	12.8	169
46	Exploring the effects of transfers and readmissions on trends in population counts of hospital admissions for coronary heart disease: a Western Australian data linkage study. BMJ Open, 2017, 7, e019226.	1.9	8
47	Neutral associations of testosterone, dihydrotestosterone and estradiol with fatal and nonâ€fatal cardiovascular events, and mortality in men aged 17–97 years. Clinical Endocrinology, 2016, 85, 575-582.	2.4	31
48	Long-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort study. BMJ Open, 2016, 6, e014397.	1.9	8
49	Long-term all-cause and cardiovascular mortality following incident myocardial infarction in men and women with and without diabetes: Temporal trends from 1998 to 2009. European Journal of Preventive Cardiology, 2016, 23, 1273-1281.	1.8	10
50	Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). American Heart Journal, 2016, 177, 58-65.	2.7	33
51	Epidemiological and Mendelian Randomization Studies of Dihydrotestosterone and Estradiol and Leukocyte Telomere Length in Men. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1299-1306.	3.6	37
52	Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995–2010. International Journal of Cardiology, 2016, 208, 19-25.	1.7	40
53	Is the incidence of heart attack still decreasing in Australia? Developing reliable methods for monitoring trends in myocardial infarction and coronary heart disease (AUS-MOCHA): a study protocol. BMJ Open, 2016, 6, e012180.	1.9	1
54	Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. Heart Lung and Circulation, 2016, 25, 520-525.	0.4	50

#	Article	IF	Citations
55	A cohort study: temporal trends in prevalence of antecedents, comorbidities and mortality in Aboriginal and non-Aboriginal Australians with first heart failure hospitalization, 2000–2009. International Journal for Equity in Health, 2015, 14, 66.	3.5	11
56	Severity of OSA Is an Independent Predictor of Incident Atrial Fibrillation Hospitalization in a Large Sleep-Clinic Cohort. Chest, 2015, 148, 945-952.	0.8	148
57	Initial hospitalisation for atrial fibrillation in Aboriginal and non-Aboriginal populations in Western Australia. Heart, 2015, 101, 712-719.	2.9	31
58	Improving 30-day case fatality after incident myocardial infarction in people with diabetes between 1998 and 2010. Heart, 2015, 101, 1318-1324.	2.9	8
59	Age-specific Gender Differences in Long-term Recurrence and Mortality following Incident Myocardial Infarction: A Population-based Study. Heart Lung and Circulation, 2015, 24, 442-449.	0.4	9
60	Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events (CONCORDANCE). American Heart Journal, 2015, 170, 566-572.e1.	2.7	26
61	Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol. BMJ Open, 2014, 4, e006258-e006258.	1.9	11
62	Comparative Trends in the Incidence of Hospitalized Myocardial Infarction and Coronary Heart Disease in Adults With and Without Diabetes Mellitus in Western Australia From 1998 to 2010. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 708-717.	2.2	14
63	A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. European Journal of Epidemiology, 2014, 29, 181-190.	5.7	99
64	Incidence of first heart failure hospitalisation and mortality in Aboriginal and non-Aboriginal patients in Western Australia, 2000–2009. International Journal of Cardiology, 2014, 173, 110-117.	1.7	34
65	A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome. BMC Medical Genetics, 2013, 14, 15.	2.1	73
66	Rationale, design and methods for a community-based study of clustering and cumulative effects of chronic disease processes and their effects on ageing: the Busselton healthy ageing study. BMC Public Health, 2013, 13, 936.	2.9	45
67	Resection of Left Ventricular Rhabdomyosarcoma. Journal of the American College of Cardiology, 2013, 62, e243.	2.8	2
68	Trends From 1996 to 2007 in Incidence and Mortality Outcomes of Heart Failure After Acute Myocardial Infarction: A Populationâ€Based Study of 20Â812 Patients With First Acute Myocardial Infarction in Western Australia. Journal of the American Heart Association, 2013, 2, e000172.	3.7	85
69	Body mass index and waist circumference: Relationship to cardiometabolic risk factors in children – B usselton H ealth S tudy 2005–2007. Journal of Paediatrics and Child Health, 2013, 49, 955-962.	0.8	10
70	Trends in long-term cardiovascular mortality and morbidity in men and women with heart failure of ischemic versus non-ischemic aetiology in Western Australia between 1990 and 2005. International Journal of Cardiology, 2012, 158, 405-410.	1.7	29
71	Can we monitor heart attack in the troponin era: evidence from a population-based cohort study. BMC Cardiovascular Disorders, 2011, 11, 35.	1.7	33
72	Age- and Sex-Specific Trends in the Incidence of Hospitalized Acute Coronary Syndromes in Western Australia. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 557-564.	2.2	65

#	Article	IF	CITATIONS
73	The effect of evidenceâ€based medication use on longâ€term survival in patients hospitalised for heart failure in Western Australia. Medical Journal of Australia, 2010, 192, 306-310.	1.7	21
74	Heart Failure. Circulation: Heart Failure, 2010, 3, 236-243.	3.9	83
75	Treatment disparities and effect on late mortality in patients with diabetes presenting with acute myocardial infarction: observations from the ACACIA registry. Medical Journal of Australia, 2009, 191, 539-543.	1.7	18
76	Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 235-241.	2.8	46
77	A validation study: how effective is the Hospital Morbidity Data as a surveillance tool for heart failure in Western Australia?. Australian and New Zealand Journal of Public Health, 2008, 32, 405-407.	1.8	62
78	Prevalence and Risk Factor Correlates of Elevated C-Reactive Protein in an Adult Australian Population. American Journal of Cardiology, 2008, 101, 193-198.	1.6	46
79	C-Reactive Protein and Interleukin-18 Levels in Relation to Coronary Heart Disease: Prospective Cohort Study from Busselton Western Australia. Heart Lung and Circulation, 2008, 17, 90-95.	0.4	16
80	Elevated Interleukin-18 Levels Are Associated With the Metabolic Syndrome Independent of Obesity and Insulin Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1268-1273.	2.4	211
81	Aspirin for cardiovascular disease prevention. Medical Journal of Australia, 2004, 180, 94-94.	1.7	0
82	Promoter polymorphism of the gene for CD14 receptor is not associated with sub-clinical carotid atherosclerosis in a community population. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, $11$ , $344$ - $349$ .	2.8	7
83	Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia. BMJ: British Medical Journal, 2003, 326, 131-131.	2.3	50
84	Aspirin for cardiovascular disease prevention. Medical Journal of Australia, 2003, 179, 147-152.	1.7	46
85	Hyperhomocysteinemia but Not the C677T Mutation of Methylenetetrahydrofolate Reductase Is an Independent Risk Determinant of Carotid Wall Thickening. Circulation, 1999, 99, 2383-2388.	1.6	187
86	The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils. British Journal of Clinical Pharmacology, 1998, 46, 139-145.	2.4	17